Phaseline

Companies › ARS Pharmaceuticals

ARS Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 12 registered trials: 5 Phase 2, 3 Phase 4, 3 Phase 3, 1 Phase 1; Immunology, Cardiovascular, Genitourinary, Oncology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Epinephrine
Adrenergic receptor agonist
ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2CPhase 4Allergic Reactions; Knee Arthroplasty, Total; Cardiac Arrest, Out-Of-Hospital; Shock Hypovolemic …Apr 2027
ARS-2–Phase 2Urticaria ChronicJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06456255EpinephrinePhase 2Sinus DiseaseOtherMay 2025
NCT04750070EpinephrinePhase 3Shock HypovolemicGenitourinaryJul 2025
NCT06920173EpinephrinePhase 2ShockOtherDec 2025
NCT07733167EpinephrinePhase 3Intra-Prostatic Epinephrine Injection in Bipolar Transurethral Resection of Large ProstatePsychiatryMar 2026
NCT06847568EpinephrinePhase 3ST Segment Elevation Myocardial Infarction (STEMI)CardiovascularApr 2026
NCT07038746EpinephrinePhase 1HypersensitivityOtherDec 2026
NCT06834165EpinephrinePhase 4Allergic ReactionsImmunologyApr 2027
NCT06927999ARS-2Phase 2Urticaria ChronicImmunologyJun 2027
NCT07089251EpinephrinePhase 4Knee Arthroplasty, TotalImmunologyJun 2027
NCT05166343EpinephrinePhase 2Pediatric Out-of-Hospital Cardiac ArrestCardiovascularJan 2028
NCT03826524EpinephrinePhase 4Cardiac Arrest, Out-Of-HospitalCardiovascularDec 2028
NCT07392580EpinephrinePhase 2Laryngeal Squamous Cell CarcinomaOncologySep 2031

From the company's SEC filings

Cash and short-term investments of $138m on 2026-09-30; operating cash outflow about $187m a year; runway about 9 months at that burn, to Jun 2027; 1 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Targets

ADRA1A (1) ADRA2A (1) ADRB1 (1) ADRB2 (1) ADRA2C (1)

Companies with the same targets

Acer Therapeutics Santen SAS Chiesi Farmaceutici AstraZeneca Opus Genetics Guangzhou Novaken Pharm BioXcel Therapeutics Teikoku Pharma USA Tecnoquimicas Tarian Pharma

Companies built like this

Acer Therapeutics Tarian Pharma Karyopharm Therapeutics Enlivex Therapeutics Arthrosi Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.